Aroor 2015 Diabetes: Difference between revisions
No edit summary |
Beno Marija (talk | contribs) No edit summary |
||
Line 16: | Line 16: | ||
|diseases=Diabetes | |diseases=Diabetes | ||
|couplingstates=LEAK, ROUTINE, OXPHOS, ETS | |couplingstates=LEAK, ROUTINE, OXPHOS, ETS | ||
| | |pathways=F, N, S, NS | ||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|additional=MitoFit news, ย | |additional=MitoFit news, | ||
}} | }} | ||
[[Image:Logo MitoFit.jpg|right|120px|link=http://www.mitofit.org/index.php/MitoFit|MitoFit]] | [[Image:Logo MitoFit.jpg|right|120px|link=http://www.mitofit.org/index.php/MitoFit|MitoFit]] | ||
== MitoFit news 2015#12 == | == MitoFit news 2015#12 == | ||
* 2015-07-16: High fat/high fructose and modulation of hepatic mitochondrial function. ยป [[MitoFit news]] | * 2015-07-16: High fat/high fructose and modulation of hepatic mitochondrial function. ยป [[MitoFit news]] |
Revision as of 15:29, 7 November 2016
Aroor AR, Habibi J, Ford DA, Nistala R, Lastra G, Manrique C, Dunham MM, Ford KD, Thyfault JP, Parks EJ, Sowers JR, Rector RS (2015) Dipeptidyl peptidase-4 inhibition ameliorates western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 64:1988-2001. |
Aroor AR, Habibi J, Ford DA, Nistala R, Lastra G, Manrique C, Dunham MM, Ford KD, Thyfault JP, Parks EJ, Sowers JR, Rector RS (2015) Diabetes
Abstract: Novel therapies are needed for treating the increasing prevalence of hepatic steatosis in western populations. In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently been reported to attenuate the development of hepatic steatosis, but the potential mechanisms remain poorly defined. In the current study, four week old C57Bl/6 mice were fed a high fat/high fructose western diet (WD) or WD containing DPP-4 inhibitor, MK0626, for 16 weeks. The DPP-4 inhibitor prevented WD-induced hepatic steatosis and reduced hepatic insulin resistance by enhancing insulin suppression of hepatic glucose output. WD-induced accumulation of hepatic triacylglycerol (TAG) and diacylglycerol (DAG) content was significantly attenuated with DPP-4 inhibitor treatment. In addition, MK0626 significantly reduced mitochondrial incomplete palmitate oxidation and increased indices of pyruvate dehydrogenase activity, TCA cycle flux, and hepatic TAG secretion. Furthermore, DPP4-inhibition rescued WD-induced decreases in hepatic PGC-1ฮฑ and CPT-1 mRNA expression and hepatic Sirt1 protein content. Moreover, plasma uric acid levels in WD fed mice were decreased after MK0626 treatment. These studies suggest that DPP-4 inhibition ameliorates hepatic steatosis and insulin resistance by suppressing hepatic TAG and DAG accumulation through enhanced mitochondrial carbohydrate utilization and hepatic TAG secretion/export with concomitant reduction of uric acid production. โข Keywords: Lipidomics, NAFLD, Obesity, Hepatic insulin resistance, MK-0626 (DPP-4 inhibitor)
โข O2k-Network Lab: US MO Columbia Rector RS
Labels: MiParea: Respiration, Exercise physiology;nutrition;life style, Pharmacology;toxicology
Pathology: Diabetes
Organism: Mouse Tissue;cell: Liver Preparation: Isolated mitochondria
Coupling state: LEAK, ROUTINE, OXPHOS, ETS"ETS" is not in the list (LEAK, ROUTINE, OXPHOS, ET) of allowed values for the "Coupling states" property.
Pathway: F, N, S, NS
HRR: Oxygraph-2k
MitoFit news
MitoFit news 2015#12
- 2015-07-16: High fat/high fructose and modulation of hepatic mitochondrial function. ยป MitoFit news